Polyclav

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Polyclav

Polyclav is a recognized trade name for the combination drug Amoxicillin-potassium clavulanate, which is a highly specialized broad-spectrum antibacterial drug. It is globally recognized for its critical role in managing bacterial infections, particularly where resistance is a major concern, as supported by its consistent inclusion on the WHO Essential Medicines List.

Property Description
Active Ingredients Amoxicillin, Clavulanic Acid
Forms Tablet, Oral Suspension, Injectable Solution
Pharmacological Class Penicillins in combination with beta-Lactamase Inhibitors
General Purpose Treatment of bacterial infections
Origin Synthetic / Semi-synthetic

Polyclav: Identity, Composition, and Pharmacological Class

This preparation is defined by its fixed-dose, dual-agent composition: the primary beta-Lactam antibiotic Amoxicillin and the adjunct ingredient Clavulanic Acid. As a semi-synthetic derivative of penicillin, Amoxicillin provides the necessary bactericidal action against susceptible pathogens. The defining characteristic is the inclusion of Clavulanic Acid, which is a mechanism-based inhibitor designed to neutralize bacterial enzymes known as beta-Lactamases. This dual composition makes it a highly differentiated treatment option within its pharmacological class.


The Synergistic Purpose of Amoxicillin and Clavulanic Acid

The core therapeutic purpose of this formulation is rooted in the synergistic effect achieved by the two components, ensuring an antibiotic system capable of overcoming widespread bacterial resistance. By protecting Amoxicillin from enzymatic degradation, Clavulanic Acid effectively restores and extends the antibiotic's spectrum of activity. This combined approach is frequently employed in clinical practice to ensure the effective infection treatment of conditions caused by resistant bacteria.


Available Pharmaceutical Forms and Administration Type

Polyclav is manufactured in several distinct dosage forms to facilitate various treatment regimens, including film-coated tablets and oral suspension (prepared from a powder) for oral administration. For situations requiring immediate high plasma concentrations, a powder used to prepare a solution for intravenous administration is also available. These forms allow for the systemic delivery of the active compounds.

What side effects are possible with Polyclav?

Possible Side Effects and Safety Information

General Adverse Reactions

The most commonly reported adverse reactions associated with Polyclav (amoxicillin/clavulanate) are primarily gastrointestinal in nature. These include diarrhea, nausea, and vomiting. Other common reactions include skin rash, pruritus (itching), and mucocutaneous candidiasis (yeast infection).

Serious and Clinically Significant Risks

Regulatory warnings emphasize the potential for serious adverse events. Severe hypersensitivity reactions (allergic reactions), including anaphylaxis and severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome, have been reported and may be fatal. Therapy must be discontinued immediately if any severe allergic reaction occurs.

There is a risk of hepatic dysfunction, including hepatitis and cholestatic jaundice, which can be severe. This reaction is reported more frequently in elderly patients, males, and those on prolonged treatment, though it can occur in any population. Additionally, antibiotic-associated colitis (including Clostridioides difficile-associated diarrhea or pseudomembranous colitis) must be considered if severe diarrhea develops during or after treatment.

Safety Precautions and Restrictions

Polyclav is contraindicated in patients with a history of hypersensitivity to any penicillin or a history of drug-associated cholestatic jaundice or hepatic dysfunction.

Caution is advised in patients with renal impairment, as dosage adjustments are typically required to prevent drug accumulation and risk of convulsions. Patients with pre-existing hepatic impairment should be closely monitored. Use is generally not recommended in patients with infectious mononucleosis due to an increased risk of developing a generalized erythematous rash.

Overdose and Emergency Response

Polyclav is a combination of amoxicillin and clavulanate potassium (a known combination product) for which specific overdose information is documented in major authoritative drug references.

Overdose Symptoms and Presentations

Acute overdose with this combination product is generally associated with gastrointestinal symptoms, fluid and electrolyte imbalance, and in rare cases, other systemic effects. Documented presentations of an overdose may include severe nausea, vomiting, and diarrhea. Reduced urination, which may present as decreased frequency or amount of urine, is a recognized symptom associated with high exposure levels, along with potential drowsiness or hyperactivity.

When to Seek Emergency Medical Help

Immediate medical attention is required for any suspected overdose or if the following serious symptoms occur at any time while taking the medication:

  • Signs of severe allergic reaction: Hives, swelling of the face, throat, or tongue, or difficulty breathing.
  • Signs of liver injury: Yellowing of the skin or eyes (jaundice), dark urine, or severe, persistent stomach pain.
  • Signs of kidney impairment: Greatly decreased urination or cloudy/bloody urine.
  • Signs of serious neurological effects: Seizures or extreme drowsiness leading to an inability to wake up.

If an overdose is suspected, promptly contact emergency medical services or a poison control center for guidance. Symptomatic and supportive treatment is necessary, often focusing on managing the gastrointestinal effects and maintaining adequate hydration and renal function.

Therapeutic Uses of Polyclav

What Polyclav Treats: Main Uses and Benefits

The therapeutic uses of this combination medication involve managing acute, symptomatic bacterial infections across several key domains. Polyclav is generally used to address acute symptomatic episodes in several therapeutic areas. This includes Community-Acquired Pneumonia, acute otitis media, bacterial rhinosinusitis, and infections of the skin and soft tissues such as cellulitis and abscesses, as well as Urinary Tract Infections (UTIs), including pyelonephritis.

This medication may assist with easing pronounced symptoms such as fever, persistent cough, severe ear pain, or facial pressure. It is often applied in situations where additional symptomatic support is needed, for instance, when managing infections resulting from animal or human bites, or in clinical settings that involve acute or unstable symptom patterns.

“This medication contributes to easing the overall symptom load and supports patients during difficult episodes by easing the impact of infection-related discomfort and inflammation.”

The medication plays a role in managing symptoms that interfere with daily functioning, such as painful and frequent urination or acute localized swelling.

Quick Fact: Relief for Acute Discomfort
Supports patients during episodes of heightened discomfort and is applied across domains where additional symptomatic support is needed.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Polyclav?

Polyclav (amoxicillin/clavulanate) is an antibiotic combination generally allowed for use in adults and children for the treatment of susceptible bacterial infections.

Contraindications (Must NOT Use):

  • Allergy and Hypersensitivity: Individuals with a known history of allergy or severe hypersensitivity reaction (e.g., anaphylaxis) to amoxicillin, clavulanic acid, or any other penicillin or beta-lactam antibiotic (like cephalosporins) are strictly contraindicated.
  • Liver Disease History: Patients who have previously developed cholestatic jaundice or hepatic dysfunction associated with the use of amoxicillin/clavulanate must not use this medicine.

Restrictions and Special Considerations:

Population/Condition Eligibility Status (Regulatory Basis)
Infectious Mononucleosis Use Not Recommended (Avoid) due to increased risk of a non-allergic skin rash.
Severe Renal Impairment Restricted/Limited Use (Dosage Adjustment Required). High-dose formulations (e.g., 875 mg amoxicillin) are contraindicated in patients with Creatinine Clearance < 30 mL/min.
Hepatic Impairment Use with Caution; close monitoring of liver function tests is advised.
Pregnancy/Lactation Use with Caution; recommended only if clearly necessary after assessing the benefit-risk profile.

Eligibility for Polyclav is defined by a primary set of absolute contraindications (allergy and past liver injury) and a secondary set of restrictions requiring caution or dosage modification (renal and hepatic impairment). The drug is otherwise generally suitable for use across adult and pediatric populations for its approved infectious disease indications.

What should I know about interactions with other medicines?

Polyclav Interactions with other medicines and products

The interaction profile for Polyclav (Amoxicillin-potassium clavulanate) is officially documented across several categories, primarily involving pharmacokinetic alterations and pharmacodynamic effects on other medicinal products, as stated in regulatory labels.

  • Probenecid: Co-administration is not recommended as this agent is documented to inhibit the renal tubular secretion of amoxicillin. This pharmacokinetic effect results in increased and prolonged plasma concentrations of the amoxicillin component.
  • Oral Anticoagulants: Concurrent use may result in the prolongation of prothrombin time (INR), an effect which requires appropriate monitoring of coagulation parameters.
  • Oral Contraceptives: Use with combined oral estrogen/progesterone contraceptives may officially reduce the efficacy of the contraceptive agent.
  • Allopurinol: The co-administration of Allopurinol is associated with a formally documented increased incidence of rash.
  • Interaction with Food: Official documentation notes that the bioavailability of the clavulanate component is greater when administered with food compared to a fasted state.
  • Clearance and Population: Dosage adjustment is formally recommended for patients with severe renal impairment (Glomerular Filtration Rate < 30 mL/ min) to account for altered clearance of the drug components.
  • Laboratory Tests: High urine concentrations of amoxicillin can cause false-positive reactions when testing for urine glucose using non-enzymatic methods.

Mechanism of Action

Irreversible Inhibition of Bacterial Cell Wall Synthesis

This core mechanism involves the amoxicillin component binding irreversibly to bacterial enzymes (Penicillin-Binding Proteins, or PBPs). This action halts the final cross-linking step of the peptidoglycan layer. This failure in cell wall construction causes the bacteria to lose structural integrity and undergo lysis (destruction), which results in the rapid death of the bacterial cell (bactericidal activity).


️ Mechanistic Protection Against Resistance

This synergistic domain involves clavulanic acid targeting and neutralizing bacterial beta-lactamase enzymes via irreversible inhibition. By eliminating this enzymatic defense, clavulanic acid shields amoxicillin from degradation, ensuring that the main drug remains intact to reach its PBP targets. This action permits the amoxicillin component to inhibit PBPs in bacteria that produce beta-lactamase, which facilitates the reduction of the bacterial population.


Cascade to Systemic Effect

The simultaneous actions of cell wall disruption and resistance negation initiate a rapid mechanistic cascade resulting in the widespread death and clearance of susceptible bacterial populations. This reduction in the pathogenic load is the physiological consequence that results in a decrease in the bacterial burden.

Dosage and Administration Information

How to Use Polyclav: Official Administration Guidelines

Polyclav (Amoxicillin-potassium clavulanate) must be administered according to specific procedural requirements to ensure the correct drug ratio and absorption.

Administration Requirements

  • Timing: The medication must be taken at the start of a meal to enhance the absorption of the clavulanate component and help minimize potential gastrointestinal discomfort.
  • Routes and Forms: The standard route is Oral (tablet, suspension, chewable tablet). An Intravenous (IV) solution for injection is also an approved route for use in clinical settings, particularly for severe infections.
Adult Dosing Regimen (Amoxicillin/Clavulanate) Frequency Pattern Key Restriction
875 mg/125 mg or 500 mg/125 mg Every 12 hours (q12h) 875 mg dose prohibited in severe renal impairment (CrCl < 30 mL/min)
500 mg/125 mg or 250 mg/125 mg Every 8 hours (q8h) Duration typically 7 to 10 days; not to exceed 14 days.

Form-Specific Instructions

  • Extended-Release (XR) Tablets must be swallowed whole; they must not be crushed, broken, or chewed. The recommended dose is two 1000 mg/62.5 mg tablets administered every 12 hours.
  • Oral Suspensions must be reconstituted with the specified amount of water and shaken well before each use. Dosage for children is weight-based, usually calculated in mg/kg/day of the amoxicillin component.
  • Substitution: Tablets with different Amoxicillin-to-Clavulanate ratios are not interchangeable; for example, two 250 mg/125 mg tablets cannot be used as a substitute for one 500 mg/125 mg tablet.

Population Adjustments

Patients with severe renal impairment (CrCl < 10 mL/min) require the frequency to be reduced to once daily (q24h). Patients with hepatic impairment should be dosed with caution, and hepatic function must be monitored at regular intervals.

Recent Clinical Evidence

Research evidence / Overview of studies for Polyclav

Evidence for use in Community-Acquired Pneumonia (CAP)

Research has explored the use of Polyclav in the context of Community-Acquired Pneumonia (CAP). Studies that have monitored patient populations include large-scale Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined outcomes related to systemic or functional imbalance, such as clinical resolution or failure, and the risk of hospitalization or all-cause mortality over defined time intervals. These studies were evaluated in both adults, including older adults, and children.

Some research conducted during periods of increased symptom activity in pediatric patients reported measurements of the cure rate that were observed as different in the combination group compared to Amoxicillin alone. Conversely, systematic reviews that performed indirect comparisons in adult populations indicated that comparative evidence between the two regimens was not established regarding clinical resolution.

Evidence for use in Acute Otitis Media (AOM) and Bacterial Rhinosinusitis (ABRS)

Research explored the research base for this medication in the context of Acute Otitis Media (AOM) and Acute Bacterial Rhinosinusitis (ABRS). The research examined includes double-blind RCTs that monitored patient-reported outcomes describing perceived discomfort. Studies explored outcomes including clinical cure rates, the time required for symptom changes to be measured, and the need for further therapeutic intervention.

Systematic reviews reported that in a portion of RCTs, the combination was associated with clinical outcomes that were comparable to other antimicrobials or placebo. Some studies reported measurements that observed rates of pathogen eradication in culture that were different when comparing the combination group to certain other antimicrobials. However, some meta-analyses reported that the findings were mixed, and results could not be fully evaluated due to substantial heterogeneity between the studies included.

What is still uncertain about Polyclav

Evidence highlights what is known and what is still uncertain across the research landscape. A key research limitation is that comparative evidence is often lacking, particularly in the form of head-to-head RCTs against Amoxicillin alone for all indicated uses. Findings were sometimes mixed or inconsistent across different systematic reviews, and certainty remains low in certain areas due to the heterogeneity of trial designs. Data for certain groups remain insufficient, and long-term effects are not fully established, making this an area where research is ongoing.

Key Studies & References

  1. Diagnosis and Treatment of Community-Acquired Pneumonia in Children and Adults
  2. What evidence supports the recommendation for high-dose amoxicillin in children with acute otitis media? [UIC Drug Information Group Analysis]
  3. Amoxicillin-clavulanate is now available IV [Alberta Health Services Formulary Guidelines mentioning SSTI RCTs]
  4. Proposal for the addition of the 875 mg + 125 mg oral amoxicillin + clavulanic acid formulation to the WHO Model List of Essential Medicines

Frequently Asked Questions (FAQ)

Common questions about Polyclav (FAQ)


Q: What is the main difference between Polyclav and other similar products?

The key difference is the addition of Clavulanic Acid to Amoxicillin. Regulatory documents state that Clavulanic Acid is intended to protect the Amoxicillin component from being destroyed by certain bacterial enzymes called beta-lactamase. This combined action helps extend the drug's activity to resistant bacteria, differentiating it within its class.


Q: Is it necessary to take Polyclav at the exact same time every day?

Official product information sets a fixed schedule for the medication, such as every 8 or 12 hours. Taking the drug at these regular intervals is important to help maintain consistent drug concentration in the body. This consistency supports the intended therapeutic effect of the medication.


Q: Do I need to change my diet while on Polyclav?

Official product information indicates that the medication is intended to be taken at the start of a meal. This timing is recommended because it helps improve the absorption of the clavulanate component and may lessen potential stomach discomfort. Official regulatory documents do not generally mandate other specific changes to a patient's diet.


Q: How does Polyclav affect the body's natural processes?

The primary effect of the medication is focused on bacteria, but it can also affect the body’s natural balance of microorganisms. Official adverse reaction lists note that this disruption may contribute to conditions like Clostridioides difficile-associated diarrhea (CDAD). The labels also describe rare but serious blood cell disorders as potential, though uncommon, adverse reactions.


Q: Are there specific lab tests required before starting Polyclav?

Official product warnings indicate that monitoring of hepatic (liver) and renal (kidney) function is advised. This monitoring is typically recommended for individuals with pre-existing organ impairment or when the medication is used for prolonged courses of treatment.


Q: Is there an age limit for taking Polyclav?

The medication is authorized for use in both adults and children. Regulatory guidelines provide specific weight-based dosage instructions for pediatric use, including established protocols for neonates and infants under 12 weeks of age.


Q: What are the signs of a serious allergic reaction to Polyclav?

Severe hypersensitivity reactions (allergic reactions) can occur. The signs of a severe reaction may include swelling of the face, throat, or tongue, difficulty breathing, a generalized severe rash, or blistering of the skin. Official documents indicate that therapy must be discontinued immediately if such reactions develop.


Q: Does Polyclav have a black box warning from the FDA?

The FDA uses prominent warnings on labels to highlight severe and clinically significant risks. While the specific term 'black box warning' may not be present, official product information strongly warns about the risk of severe hypersensitivity reactions (anaphylaxis) and the potential for serious hepatic (liver) dysfunction.


Q: Is Polyclav safe for people with diabetes?

According to official product information, Polyclav can affect certain laboratory tests for glucose. High concentrations of the amoxicillin component in the urine can lead to false-positive results when testing for urine glucose using non-enzymatic methods.


Q: What are the signs that Polyclav is starting to work?

The drug’s mechanism is described as bactericidal, meaning it actively causes the rapid death and destruction of susceptible bacterial cells. The consequence of this action is the reduction of the pathogenic load, which is intended to result in a measurable reduction of infection symptoms.


Q: How long after taking Polyclav can I drive a car?

Regulatory information notes that central nervous system effects are among the potential adverse reactions. Effects such as dizziness and convulsions have been reported, and these may impair a person's ability to safely drive or operate heavy machinery.


Q: Does Polyclav cause weight gain or weight loss?

Official product information lists both loss of appetite and unusual weight loss among potential adverse reactions. These effects are reported in post-marketing experience, meaning they have a low or unknown incidence.


Q: Does Polyclav affect a person's ability to concentrate or memory?

The official adverse reaction profile notes the possibility of central nervous system (CNS) effects, such as convulsions. While concentration or memory issues are not explicitly listed as common reactions, any CNS effect may indirectly affect attention.


Q: Why do people say that Polyclav is a powerful medication?

People describe Polyclav as powerful because of its unique composition and synergistic action. The Clavulanic Acid component is intended to address a key defense mechanism used by bacteria (beta-lactamase), which helps the Amoxicillin component act against bacterial strains that have developed resistance to Amoxicillin alone.


Q: Is it normal to feel slightly dizzy when starting Polyclav?

Dizziness is listed as a potential side effect associated with the medication in the official product information. This effect is part of the central nervous system adverse reaction profile described in regulatory documentation.


Q: Does Polyclav make a person more sensitive to sunlight?

Official drug documents for this medication do not typically list photosensitivity reactions (increased sensitivity to sunlight) as a known adverse effect.


Q: How long does Polyclav stay in the system after the last dose?

The elimination half-life of the active components is listed in the official pharmacokinetic data as approximately one hour. This half-life is a key measure used by regulators to determine the rate at which the medication is cleared from the systemic circulation, primarily through the kidneys.


Q: What is the difference in effect between the tablet and capsule forms of Polyclav?

Different pharmaceutical forms, such as standard tablets versus liquid suspension, have distinct profiles that affect how the drug is absorbed. The regulatory administration rules and differences in composition (e.g., extended-release properties) are intended to support the achievement of the correct drug concentration in the body.


Q: Why might Polyclav fail to work for some people?

The official product information specifies that the drug is indicated only for infections caused by susceptible bacteria. Failure may occur if the infection is caused by a resistant organism that the Clavulanic Acid component is not intended to inhibit.


Q: Does Polyclav affect fertility in men or women?

According to public health data aligned with regulatory reviews, there is insufficient evidence to definitively determine the effect of this medication on male or female fertility. Official documents reflect that the drug should be used only if clearly necessary, following an assessment of the benefit-risk profile.


Q: Why is Polyclav only available by prescription?

The drug is classified as a Prescription Only Medicine (POM) by regulatory authorities globally. This status is assigned due to its defined risk profile, the necessity for clinical diagnosis of the infection, and to support appropriate antibiotic stewardship to help prevent resistance.

How should Polyclav be stored and disposed of?

How to Store and Dispose of Polyclav (Amoxicillin and Clavulanate Potassium)

Official regulatory guidelines define specific storage requirements that differ between the dry product and the liquid suspension.

Storage Requirements

Dosage Form Temperature Mandate Protection/Container Rule
Unmixed Tablets/Powder Store at Controlled Room Temperature (below 25°C) Keep in original, tightly closed container; protect from moisture and light.
Reconstituted Suspension Must be refrigerated (2°C to 8°C); Do not freeze. Must be kept out of the sight and reach of children.

Stability and Disposal

The reconstituted liquid suspension must be discarded after 10 days of refrigeration. Unused or expired medication should be disposed of via a medicine take-back program or by following specific government guidelines for household trash. The medicine must not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Polyclav found in:

A-Z Index: